Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice.

ABSTRACT: Melanoma is the deadliest type of skin cancer with one of the fastest increasing incidence rates among solid tumors. The use of checkpoint inhibitors (e.g. αPD-1 antibody) has recently emerged as a viable alternative to conventional modes of therapy. However, increasing evidence points towards the need for a tumor priming step to improve intratumoral immune cell infiltration. IL-12 is an immune-activating cytokine with such potential and was explored in earlier clinical trials as a highly concentrated systemic infusion. This unfortunately led to severe adverse effects. From this perspective, the localization and gradual release of such a potent immunotherapeutic agent in the tumor microenvironment is desired. This manuscript reports the use of a heparin-based complex coacervate to deliver

SUBMITTER: Hwang MP 

PROVIDER: S-EPMC7045464 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature